The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy

Journal of the American College of Cardiology

Volumn 68, Issue 21, 2016, Pages 2348-2364

  Heymans, Stephane ^a   Eriksson, Urs ^b   Lehtonen, Jukka ^c   Cooper, Leslie T ^d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d MAYO CLINIC   (United States)

Author keywords

heart failure; inflammasomes; macrophages; microRNAs; sarcoidosis; t lymphocyte subsets; viral infection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RNA;

ATHLETE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CAUSE OF DEATH; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ELECTROGRAPHY; HEART MUSCLE BIOPSY; HISTOPATHOLOGY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFLAMMATION; INFLAMMATORY CARDIOMYOPATHY; MACROPHAGE; MORTALITY; MYOCARDITIS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; T LYMPHOCYTE; VIRUS INFECTION; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHIES; CELLULAR IMMUNITY; COMPLICATION; GLOBAL HEALTH; IMMUNOLOGY; INCIDENCE; PATHOLOGY;

BIOPSY; CARDIOMYOPATHIES; GLOBAL HEALTH; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; MYOCARDITIS; MYOCARDIUM; PROGNOSIS; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 84997824398     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.937     Document Type: Review

References (176)

1. 1 Cooper, L.T. Jr., Myocarditis. N Engl J Med 360 (2009), 1526–1538.
2. 2 Dennert, R., Crijns, H.J., Heymans, S., Acute viral myocarditis. Eur Heart J 29 (2008), 2073–2082.
3. 3 Caforio, A.L.P., Pankuweit, S., Arbustini, E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 (2013), 2636–2648.
4. 4 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
5. 5 Cooper, L.T. Jr., Keren, A., Sliwa, K., et al. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart 9 (2014), 121–129.
6. 6 Maron, B.J., Udelson, J.E., Bonow, R.O., et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 66 (2015), 2362–2371.
7. 7 Matoba, R., Shikata, I., Iwai, K., et al. An epidemiologic and histopathological study of sudden cardiac death in Osaka Medical Examiner's Office. Jpn Circ J 53 (1989), 1581–1588.
8. 8 Kandolin, R., Lehtonen, J., Airaksinen, J., et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131 (2015), 624–632.
9. 9 Roberts, W.C., McAllister, H.A. Jr., Ferrans, V.J., Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 63 (1977), 86–108.
10. 10 Hazebroek, M.R., Moors, S., Dennert, R., et al. Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol 66 (2015), 1313–1323.
11. 11 Cooper, L.T. Jr., Hare, J.M., Tazelaar, H.D., et al., for the Giant Cell Myocarditis Treatment Trial Investigators. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102 (2008), 1535–1539.
12. 12 Kandolin, R., Lehtonen, J., Salmenkivi, K., et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Failure 6 (2013), 15–22.
13. 13 Ekström, K., Lehtonen, J., Kandolin, R., et al. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Failure, 2016 Jul 13 [E-pub ahead of print].
14. 14 Whitehead, R., Isolated myocarditis. Brit Heart J 27 (1965), 220–230.
15. 15 Kytö, V., Saukko, P., Lignitz, E., et al. Diagnosis and presentation of fatal myocarditis. Hum Pathol 36 (2005), 1003–1007.
16. 16 Davidoff, R., Palacios, I., Southern, J., et al. Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes. Circulation 83 (1991), 953–961.
17. 17 Schultheiss, H.P., Kühl, U., Cooper, L.T., The management of myocarditis. Eur Heart J 32 (2011), 2616–2625.
18. 18 Andréoletti, L., Lévêque, N., Boulagnon, C., et al. Viral causes of human myocarditis. Arch Cardiovasc Dis 102 (2009), 559–568.
19. 19 Pauschinger, M., Phan, M.D., Doerner, A., et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99 (1999), 889–895.
20. 20 Baruteau, A.E., Boimond, N., Ramful, D., Myocarditis associated with 2009 influenza A (H1N1) virus in children. Cardiol Young 20 (2010), 351–352.
21. 21 Bowles, N.E., Ni, J., Kearney, D.L., et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 42 (2003), 466–472.
22. 22 Pauschinger, M., Bowles, N.E., Fuentes-Garcia, F.J., et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99 (1999), 1348–1354.
23. 23 Matsumori, A., Yutani, C., Ikeda, Y., et al. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80 (2000), 1137–1142.
24. 24 Omura, T., Yoshiyama, M., Hayashi, T., et al. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res 96 (2005), 148–150.
25. 25 Chimenti, C., Russo, A., Pieroni, M., et al. Intramyocyte detection of Epstein-Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy. Circulation 110 (2004), 3534–3539.
26. 26 Breinholt, J.P., Moulik, M., Dreyer, W.J., et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant 29 (2010), 739–746.
27. 27 Kühl, U., Pauschinger, M., Noutsias, M., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111 (2005), 887–893.
28. 28 Ellis, N.M., Kurahara, D.K., Vohra, H., et al. Priming the immune system for heart disease: a perspective on group A streptococci. J Infect Dis 202 (2010), 1059–1067.
29. 29 Karatolios, K., Maisch, B., Pankuweit, S., Suspected inflammatory cardiomyopathy. Prevalence of Borrelia burgdorferi in endomyocardial biopsies with positive serological evidence. Herz 40 Suppl 1 (2015), 91–95.
30. 30 Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C., et al. Pathogenesis of chronic Chagas heart disease. Circulation 115 (2007), 1109–1123.
31. 31 Burke, A., Saenger, J., Mullick, F., et al. Hypersensitivity myocarditis. Arch Pathol Lab Med 115 (1991), 764–769.
32. 32 Haas, S.J., Hill, R., Krum, H., et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Safety 30 (2007), 47–57.
33. 33 Cook, S.C., Ferguson, B.A., Cotes, R.O., et al. Clozapine-induced myocarditis: prevention and considerations in rechallenge. Psychosomatics 56 (2015), 685–690.
34. 34 Engler, R.J., Nelson, M.R., Collins, L.C. Jr., et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One, 10, 2015, e0118283.
35. 35 Zawadowski, G., Klarich, K., Moder, K., et al. A contemporary case series of lupus myocarditis. Lupus 21 (2012), 1378–1384.
36. 36 Maleszewski, J.J., Orellana, V.M., Hodge, D.O., et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 115 (2015), 1733–1738.
37. 37 Ciháková, D., Sharma, R.B., Fairweather, D., et al. Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol Med 102 (2004), 175–193.
38. 38 Chow, L.H., Beisel, K.W., McManus, B.M., Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 66 (1992), 24–31.
39. 39 Eriksson, U., Ricci, R., Hunziker, L., et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9 (2003), 1484–1490.
40. 40 Kaya, Z., Katus, H.A., Rose, N.R., Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol 134 (2010), 80–88.
41. 41 Watanabe, K., Arumugam, S., Sreedhar, R., et al. Small interfering RNA therapy against carbohydrate sulfotransferase 15 inhibits cardiac remodeling in rats with dilated cardiomyopathy. Cell Signal 27 (2015), 1517–1524.
42. 42 Kandolf, R., Canu, A., Hofschneider, P.H., Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J Mol Cell Cardiol 17 (1985), 167–181.
43. 43 Bergelson, J.M., Cunningham, J.A., Droguett, G., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 (1997), 1320–1323.
44. 44 Martino, T.A., Petric, M., Brown, M., et al. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244 (1998), 302–314.
45. 45 Abston, E.D., Coronado, M.J., Bucek, A., et al. Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease. Clin Dev Immunol, 2012, 2012, 129486.
46. 46 Fairweather, D., Frisancho-Kiss, S., Rose, N., Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis. Rev Med Virol 15 (2005), 17–27.
47. 47 Bonney, K., Engman, D., Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead. Am J Pathol 185 (2015), 1537–1547.
48. 48 Mocelin, A., Issa, V., Bacal, F., et al. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Failure 7 (2005), 869–873.
49. 49 Yuan, J., Liu, Z., Lim, T., et al. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 104 (2009), 628–638.
50. 50 Jenke, A., Holzhauser, L., Löbel, M., et al. Adiponectin promotes coxsackievirus B3 myocarditis by suppression of acute anti-viral immune responses. Basic Res Cardiol, 109, 2014, 408.
51. 51 Deonarain, R., Cerullo, D., Fuse, K., et al. Protective role for interferon-β in coxsackievirus B3 infection. Circulation 110 (2004), 3540–3543.
52. 52 Huber, S.A., Sartini, D., Exley, M., Vγ4+T cells promote autoimmune CD8+ cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4+ Th1 cells. J Virol 76 (2002), 10785–10790.
53. 53 Noutsias, M., Rohde, M., Göldner, K., et al. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Failure 13 (2011), 611–618.
54. 54 Valaperti, A., Marty, R.R., Kania, G., et al. CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis. J Immunol 180 (2008), 2686–2695.
55. 55 Caforio, A.L., Marcolongo, R., Jahns, R., et al. Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management. Heart Fail Rev 18 (2013), 715–732.
56. 56 Fairweather, D., Kaya, Z., Shellam, G.R., et al. From infection to autoimmunity. J Autoimmun 16 (2001), 175–186.
57. 57 Mahrholdt, H., Wagner, A., Deluigi, C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 (2006), 1581–1590.
58. 58 Caforio, A.L., Mahon, N.J., McKenna, W.J., Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy. Autoimmunity 34 (2001), 199–204.
59. 59 Cunha-Neto, E., Bilate, A.M., Hyland, K.V., et al. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39 (2006), 41–54.
60. 60 Lauer, B., Schannwell, M., Kühl, U., et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35 (2000), 11–18.
61. 61 Blyszczuk, P., Kania, G., Dieterle, T., et al. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res 105 (2009), 912–920.
62. 62 Kania, G., Blyszczuk, P., Eriksson, U., Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 19 (2009), 247–252.
63. 63 Frieler, R.A., Mortensen, R.M., Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131 (2015), 1019–1030.
64. 64 Delgado, C., Ruiz-Hurtado, G., Gómez-Hurtado, N., et al. NOD1, a new player in cardiac function and calcium handling. Cardiovasc Res 106 (2015), 375–386.
65. 65 Gratchev, A., Kzhyshkowska, J., Kothe, K., et al. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 211 (2006), 473–486.
66. 66 Cheung, C., Luo, H., Yanagawa, B., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 15 (2006), 63–74.
67. 67 Rienks, M., Papageorgiou, A.P., Novel regulators of cardiac inflammation: matricellular proteins expand their repertoire. J Mol Cell Cardiol 91 (2016), 172–178.
68. 68 Epelman, S., Liu, P.P., Mann, D.L., Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol 15 (2015), 117–129.
69. 69 Jenke, A., Wilk, S., Poller, W., et al. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res 99 (2013), 422–431.
70. 70 Frisancho-Kiss, S., Davis, S.E., Nyland, J.F., et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 178 (2007), 6710–6714.
71. 71 Fairweather, D., Yusung, S., Frisancho, S., et al. IL-12 receptor β1 and Toll-like receptor 4 increase IL-1β- and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 170 (2003), 4731–4737.
72. 72 Riad, A., Meyer zu Schwabedissen, H., Weitmann, K., et al. Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. J Biol Chem 287 (2012), 27236–27243.
73. 73 Pagni, P.P., Traub, S., Demaria, O., et al. Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity 43 (2010), 275–287.
74. 74 Abston, E.D., Coronado, M.J., Bucek, A., et al. TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL-4. Am J Physiol Regul Integr Comp Physiol 304 (2013), R267–R277.
75. 75 Gorbea, C., Makar, K.A., Pauschinger, M., et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J Biol Chem 285 (2010), 23208–23223.
76. 76 Weithauser, A., Bobbert, P., Antoniak, S., et al. Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis. J Am Coll Cardiol 62 (2013), 1737–1745.
77. 77 Su, Z., Zhang, P., Yu, Y., et al. HMGB1 facilitated macrophage reprogramming towards a proinflammatory M1-like phenotype in experimental autoimmune myocarditis development. Sci Rep, 6, 2016, 21884.
78. 78 Eriksson, U., Kurrer, M.O., Sonderegger, I., et al. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 197 (2003), 323–331.
79. 79 Zhang, P., Cox, C.J., Alvarez, K.M., et al. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol 183 (2009), 27–31.
80. 80 Barin, J.G., Baldeviano, G.C., Talor, M.V., et al. Macrophages participate in IL-17-mediated inflammation. Eur J Immunol 42 (2012), 726–736.
81. 81 Leuschner, F., Courties, G., Dutta, P., et al. Silencing of CCR2 in myocarditis. Eur Heart J 36 (2015), 1478–1488.
82. 82 Cooper, L.T. Jr., Fairweather, D., Nano-scale treatment for a macro-scale disease: nanoparticle-delivered siRNA silences CCR2 and treats myocarditis. Eur Heart J 36 (2015), 1434–1436.
83. 83 Göser, S., Ottl, R., Brodner, A., et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1α in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112 (2005), 3400–3407.
84. 84 Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11 (2010), 889–896.
85. 85 Martinez, F.O., Sica, A., Mantovani, A., et al. Macrophage activation and polarization. Front Biosci 13 (2008), 453–461.
86. 86 Barin, J.G., Rose, N.R., Ciháková, D., Macrophage diversity in cardiac inflammation: a review. Immunobiology 217 (2012), 468–475.
87. 87 Cihakova, D., Barin, J.G., Afanasyeva, M., et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 172 (2008), 1195–1208.
88. 88 Kania, G., Blyszczuk, P., Stein, S., et al. Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of transforming growth factor β-mediated cardiac fibrosis in experimental autoimmune myocarditis. Circ Res 105 (2009), 462–470.
89. 89 Blyszczuk, P., Müller-Edenborn, B., Valenta, T., et al. Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. Eur Heart J, 2016 Apr 20 [E-pub ahead of print].
90. 90 Afanasyeva, M., Georgakopoulos, D., Belardi, D.F., et al. Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function. Am J Pathol 164 (2004), 807–815.
91. 91 Cihakova, D., Rose, N.R., Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 99 (2008), 95–114.
92. 92 Huber, S.A., Viral myocarditis and dilated cardiomyopathy: etiology and pathogenesis. Curr Pharm Des 22 (2016), 408–426.
93. 93 Lv, H., Havari, E., Pinto, S., et al. Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest 121 (2011), 1561–1573.
94. 94 Marty, R.R., Dirnhofer, S., Mauermann, N., et al. MyD88 signaling controls autoimmune myocarditis induction. Circulation 113 (2006), 258–265.
95. 95 Nindl, V., Maier, R., Ratering, D., et al. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol 42 (2012), 2311–2321.
96. 96 Chen, P., Baldeviano, G.C., Ligons, D.L., et al. Susceptibility to autoimmune myocarditis is associated with intrinsic differences in CD4+ T cells. Clin Exp Immunol 169 (2012), 79–88.
97. 97 Eriksson, U., Kurrer, M.O., Sebald, W., et al. Dual role of the IL-12/IFN-γ axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-γ. J Immunol 167 (2001), 5464–5469.
98. 98 Barin, J.G., Baldeviano, G.C., Talor, M.V., et al. Fatal eosinophilic myocarditis develops in the absence of IFN-γ and IL-17A. J Immunol 191 (2013), 4038–4047.
99. 99 Eriksson, U., Kurrer, M.O., Bingisser, R., et al. Lethal autoimmune myocarditis in interferon-γ receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation 103 (2001), 18–21.
100. 100 Afanasyeva, M., Wang, Y., Kaya, Z., et al. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-γ-independent pathway. Circulation 104 (2001), 3145–3151.
101. 101 Silverio, J.C., Pereira, I.R., Cipitelli Mda, C., et al. CD8+ T-cells expressing interferon gamma or perforin play antagonistic roles in heart injury in experimental Trypanosoma cruzi-elicited cardiomyopathy. PLoS Pathog, 8, 2012, e1002645.
102. 102 Kania, G., Siegert, S., Behnke, S., et al. Innate signaling promotes formation of regulatory nitric oxide-producing dendritic cells limiting T-cell expansion in experimental autoimmune myocarditis. Circulation 127 (2013), 2285–2294.
103. 103 Rangachari, M., Mauermann, N., Marty, R.R., et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 203 (2006), 200–219.
104. 104 Baldeviano, G.C., Barin, J.G., Talor, M.V., et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 106 (2010), 1646–1655.
105. 105 Myers, J.M., Cooper, L.T., Kem, D.C., et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight, 1, 2016, e85851.
106. 106 Ameling, S., Herda, L.R., Hammer, E., et al. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur Heart J 34 (2013), 666–675.
107. 107 Staudt, A., Böhm, M., Knebel, F., et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 106 (2002), 2448–2453.
108. 108 Caforio, A.L., Angelini, A., Blank, M., et al. Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol 179 (2015), 166–177.
109. 109 Okazaki, T., Tanaka, Y., Nishio, R., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9 (2003), 1477–1483.
110. 110 Limas, C.J., Goldenberg, I.F., Limas, C., Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 64 (1989), 97–103.
111. 111 Cocker, M.S., Abdel-Aty, H., Strohm, O., et al. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart 95 (2009), 1925–1930.
112. 112 Fairweather, D., Cooper, L.T. Jr., Blauwet, L.A., Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Problems Cardiol 38 (2013), 7–46.
113. 113 Frisancho-Kiss, S., Nyland, J.F., Davis, S.E., et al. Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rβ1 signaling and IFN-γ increase inflammation in males independent from STAT4. Brain Res 1126 (2006), 139–147.
114. 114 Frisancho-Kiss, S., Davis, S., Nyland, J., et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 178 (2007), 6710–6714.
115. 115 Frisancho-Kiss, S., Nyland, J.F., Davis, S.E., et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol 176 (2006), 6411–6415.
116. 116 Li, K., Xu, W., Guo, Q., et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 105 (2009), 353–364.
117. 117 Liu, L., Yue, Y., Xiong, S., NK-derived IFN-γ/IL-4 triggers the sexually disparate polarization of macrophages in CVB3-induced myocarditis. J Mol Cell Cardiol 76 (2014), 15–25.
118. 118 van Rooij, E., Marshall, W.S., Olson, E.N., Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103 (2008), 919–928.
119. 119 Small, E.M., Olson, E.N., Pervasive roles of microRNAs in cardiovascular biology. Nature 469 (2011), 336–342.
120. 120 Janssen, H.L., Reesink, H.W., Lawitz, E.J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 368 (2013), 1685–1694.
121. 121 Corsten, M.F., Papageorgiou, A., Verhesen, W., et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 111 (2012), 415–425.
122. 122 Yan, L., Hu, F., Yan, X., et al. Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response. J Mol Med (Berl) 94 (2016), 1063–1079.
123. 123 Zhang, Y., Zhang, M., Li, X., et al. Silencing microRNA-155 attenuates cardiac injury and dysfunction in viral myocarditis via promotion of M2 phenotype polarization of macrophages. Sci Rep, 6, 2016, 22613.
124. 124 Liu, Y.L., Wu, W., Xue, Y., et al. MicroRNA-21 and -146b are involved in the pathogenesis of murine viral myocarditis by regulating TH-17 differentiation. Arch Virol 158 (2013), 1953–1963.
125. 125 Navarro, I.C., Ferreira, F.M., Nakaya, H.I., et al. MicroRNA Transcriptome profiling in heart of Trypanosoma cruzi-infected mice: parasitological and cardiological outcomes. PLoS Negl Trop Dis, 9, 2015, e0003828.
126. 126 Corsten, M., Heggermont, W., Papageorgiou, A.P., et al. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. Eur Heart J 36 (2015), 2909–2919.
127. 127 Heymans, S., Corsten, M.F., Verhesen, W., et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 128 (2013), 1420–1432.
128. 128 Corsten, M.F., Dennert, R., Jochems, S., et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3 (2010), 499–506.
129. 129 Devaux, Y., Vausort, M., Goretti, E., et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 58 (2012), 559–567.
130. 130 Kuehl, U., Lassner, D., Gast, M., et al. Differential cardiac microRNA expression predicts the clinical course in human enterovirus cardiomyopathy. Circ Heart Fail 8 (2015), 605–618.
131. 131 Imazio, M., Brucato, A., Barbieri, A., et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation 28 (2013), 142–149.
132. 132 Foerster, S.R., Canter, C.E., Cinar, A., et al. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry. Circ Heart Failure 3 (2010), 689–697.
133. 133 Gilotra, N.A., Minkove, N., Bennett, M.K., et al. Lack of relationship between serum cardiac troponin I level and giant cell myocarditis diagnosis and outcomes. J Card Fail 22 (2016), 583–585.
134. 134 Escher, F., Kasner, M., Kühl, U., et al. New echocardiographic findings correlate with intramyocardial inflammation in endomyocardial biopsies of patients with acute myocarditis and inflammatory cardiomyopathy. Mediators Inflamm, 2013, 2013, 875420.
135. 135 Uppu, S.C., Shah, A., Weigand, J., et al. Two-dimensional speckle-tracking-derived segmental peak systolic longitudinal strain identifies regional myocardial involvement in patients with myocarditis and normal global left ventricular systolic function. Pediatr Cardiol 36 (2015), 950–959.
136. 136 Ukena, C., Mahfoud, F., Kindermann, I., et al. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Failure 13 (2011), 398–405.
137. 137 Lurz, P., Luecke, C., Eitel, I., et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial. J Am Coll Cardiol 67 (2016), 1800–1811.
138. 138 Raimondi, F., Iserin, F., Raisky, O., et al. Myocardial inflammation on cardiovascular magnetic resonance predicts left ventricular function recovery in children with recent dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 16 (2015), 756–762.
139. 139 Friedrich, M.G., Sechtem, U., Schulz-Menger, J., et al., for the International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 53 (2009), 1475–1487.
140. 140 Vermes, E., Childs, H., Faris, P., et al. Predictive value of CMR criteria for LV functional improvement in patients with acute myocarditis. Eur Heart J Cardiovasc Imaging 15 (2014), 1140–1144.
141. 141 Schumm, J., Greulich, S., Wagner, A., et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovas Magn Reson, 16, 2014, 14.
142. 142 Ekström, K., Lehtonen, J., Hänninen, H., et al. Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc, 5, 2016, e003040.
143. 143 Youssef, G., Leung, E., Mylonas, I., et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53 (2012), 241–248.
144. 144 Tung, R., Bauer, B., Schelbert, H., et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inflammation in arrhythmogenesis. Heart Rhythm 12 (2015), 2488–2498.
145. 145 Birnie, D.H., Sauer, W.H., Bogun, F., et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 (2014), 1305–1323.
146. 146 Kadkhodayan, A., Chareonthaitawee, P., Raman, S.V., Cooper, L.T., Imaging of inflammation in unexplained cardiomyopathy. J Am Coll Cardiol Img 9 (2016), 603–617.
147. 147 Blankstein, R., Osborne, M., Naya, M., et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 63 (2014), 329–336.
148. 148 Aggarwal, N.R., Snipelisky, D., Young, P.M., et al. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 16 (2015), 949–958.
149. 149 Sagar, S., Liu, P.P., Cooper, L.T. Jr., Myocarditis. Lancet 379 (2012), 738–747.
150. 150 Shields, R.C., Tazelaar, H.D., Berry, G.J., et al. The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 8 (2002), 74–78.
151. 151 Cooper, L.T. Jr., Role of left ventricular biopsy in the management of heart disease. Circulation 128 (2013), 1492–1494.
152. 152 Kandolin, R., Lehtonen, J., Kupari, M., Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 4 (2011), 303–309.
153. 153 Sperry, B.W., Oldan, J., Hachamovitch, R., et al. Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. J Heart Lung Transplant 35 (2015), 392–393.
154. 154 Liang, J.J., Hebl, V.B., DeSimone, C.V., et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. J Am Coll Cardiol HF 2 (2014), 466–473.
155. 155 Mahfoud, F., Gärtner, B., Kindermann, M., et al. Virus serology in patients with suspected myocarditis: utility or futility?. Eur Heart J 32 (2011), 897–903.
156. 156 Donoso Mantke, O., Nitsche, A., Meyer, R., et al. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. J Clin Virol 31 (2004), 32–39.
157. 157 Kuethe, F., Lindner, J., Matschke, K., et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 49 (2009), 1660–1666.
158. 158 Moimas, S., Zacchigna, S., Merlo, M., et al. Idiopathic dilated cardiomyopathy and persistent viral infection: lack of association in a controlled study using a quantitative assay. Heart Lung Circ 21 (2012), 787–793.
159. 159 Lotze, U., Egerer, R., Glück, B., et al. Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol 82 (2010), 1449–1457.
160. 160 Bonvicini, F., Manaresi, E., Di Furio, F., et al. Parvovirus B19 DNA CpG dinucleotide methylation and epigenetic regulation of viral expression. PLoS One, 7, 2012, e33316.
161. 161 Escher, S., Kuhl, U., Lassner, D., et al. Analysis of endomyocardial biopsies in cardiomyopathies: diagnostic value of left versus right ventricular biopsy (abstr). J Am Coll Cardiol, 65 Suppl 10, 2015, A930.
162. 162 Bock, C.T., Klingel, K., Kandolf, R., Human parvovirus B19-associated myocarditis. N Engl J Med 362 (2010), 1248–1249.
163. 163 Lassner, D., Kühl, U., Siegismund, C., et al. Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling. Eur Heart J 35 (2014), 2186–2195.
164. 164 Kandolin, R., Cardiac Sarcoidosis and Giant Cell Myocarditis in Finland [dissertation]. 2015, Universitatis Helsinkiensis, Helsinki, Finland.
165. 165 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
166. 166 Pinto, Y.M., Elliott, P.M., Arbustini, E., et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 37 (2016), 1850–1858.
167. 167 Wojnicz, R., Nowalany-Kozielska, E., Wojciechowska, C., et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104 (2001), 39–45.
168. 168 Frustaci, A., Russo, M.A., Chimenti, C., Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30 (2009), 1995–2002.
169. 169 Schultheiss, H., Piper, C., Sowade, O., et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 105 (2016), 763–773.
170. 170 Dennert, R., Velthuis, S., Schalla, S., et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 15 (2010), 193–201.
171. 171 Maisch, B., Hufnagel, G., Kölsch, S., et al. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz 29 (2004), 624–636.
172. 172 McNamara, D.M., Holubkov, R., Starling, R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001), 2254–2259.
173. 173 Blauwet, L.A., Cooper, L.T., Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 18 (2012), 733–746.
174. 174 Kandolin, R., Lehtonen, J., Kupari, M., Cardiac sarcoidosis. J Intern Med 280 (2016), 129–131.
175. 175 Cooper, L.T., Berry, G.J., Shabetai, R., for the Multicenter Giant Cell Myocarditis Study Group Investigators. Giant cell myocarditis: natural history and treatment. N Engl J Med 336 (1997), 1860–1866.
176. 176 Bozkurt, B., Colvin, M., Cooper, L.T., et al., on behalf of the American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation, 2016 Nov 3 [E-pub ahead of print].